MarginsXMarginsX
Home › Markets › Health Care › GILD

Gilead Sciences Inc. (GILD)

GILD trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$167.58
-0.30% on the day
Market cap
$207.9B
Mega cap
Revenue · 2025
$29.4B
+2.4% on 2024
Net income · 2025
$8.5B
28.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGILD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year1992
SEC CIK0000882095
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$29.4B
Net income$8.5B
Operating income$10.0B
Net margin28.9%
Operating margin34.0%
Revenue growth+2.4%
Cash$7.6B
Total assets$59.0B
P/E (computed)24.4×
P/S (computed)7.1×

Warning signs

Cash runway
Cash-flow positive
$6.4B cash at September 30, 2026
Share count, 1 year
0.0%
2025-10-31 to 2026-10-23 · -0.5% over 3 years
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
-$83.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$6.4B cash; operating cash flow $3.6B a quarter.Report 2026-09-30
Shares outstanding1,240,338,614 (2026-10-23); 1,240,679,623 a year earlier; 1,246,041,895 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-05-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $83.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$8.3B$2.4B$5.0B$6.4B$26.2B$31.0B10-Q 2026-10-30
Q2 2026
2026-06-30
$7.8B-$10.5B$3.6B$3.2B$26.2B$30.5B10-Q 2026-08-06
Q1 2026
2026-03-31
$7.0B$2.0B$2.5B$7.6B$22.2B$29.7B10-Q 2026-05-07
Q4 2025
2025-12-31
$7.9B$2.2B$3.3B$7.6B$24.9B$29.4B10-K 2026-02-24
Q3 2025
2025-09-30
$7.8B$3.1B$4.1B$7.3B$24.9B$29.1B10-Q 2026-10-30
Q2 2025
2025-06-30
$7.1B$2.0B$827.0M$5.1B$24.9B$28.9B10-Q 2026-08-06
Q1 2025
2025-03-31
$6.7B$1.3B$1.8B$7.9B$25.0B$28.7B10-Q 2026-05-07
Q4 2024
2024-12-31
$7.6B$1.8B$3.0B$10.0B$26.7B$28.8B10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-08-06
Latest annual report
FORM 10-K
10-K2026-02-24
Latest quarterly / interim
FORM 10-Q
10-Q2026-10-30
Latest current report
FORM 8-K
8-K2026-10-29
Latest proxy
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
DEFA14A2026-03-20

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.7%
1 month+13.6%
3 months+21.7%
Year to date+36.9%
1 year+34.2%
From 52-week high-3.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
AMGNAmgen Inc.$462.32-0.72%$250.1B
MRNAModerna Inc.$215.27-3.63%$87.1B
ARGXargenx SE$950.95-0.95%$59.0B
BIIBBiogen Inc.$251.65-0.69%$37.2B
RVMDRevolution Medicines Inc.$166.87-3.15%$36.1B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier